AUPH - Aurinia inks deal for voclosporin in Europe and Japan with Otsuka Pharma

Aurinia Pharmaceuticals (AUPH) has entered into a collaboration and license agreement with Otsuka Pharmaceutical for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis ((LN)) in the European Union ((EU)), Japan, U.K., Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. As part of the agreement, Aurinia will receive an upfront cash payment of $50M, potential milestone payments up to $50M and tiered royalties ranging from 10 to 20% on net sales. Otsuka expects to file a marketing authorization application with the EMA in Q2 2021.Voclosporin is currently under FDA review with PDUFA target action date of January 22, 2021.LN is a chronic, progressive inflammation of the kidneys that is one of the most serious complications of the autoimmune disease systemic lupus erythematosus.

For further details see:

Aurinia inks deal for voclosporin in Europe and Japan with Otsuka Pharma